Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9474724 | 0.99 | ALOX5 (0.97) | ALOX5PARP10 | |
| Ammonia Solution, Strong SCHEMBL9473339 | 0.99 | ALOX5 (0.97) | ALOX5PARP10 | |
| SCHEMBL9475019 | 0.99 | ALOX5 (0.97) | ALOX5PARP10 | |
| SCHEMBL9475027 | 0.94 | ALOX5 (0.88) | ALOX5 | |
| Tetrylammonium SCHEMBL9377970 | 0.93 | ALOX5 (0.86) | ALOX5 | |
| SCHEMBL9473489 | 0.89 | ALOX5 (0.80) | ALOX5 | |
| SCHEMBL9474936 | 0.88 | ALOX5 (0.79) | ALOX5 | |
| SCHEMBL7713248 | 0.88 | ALOX5 (0.78) | ALOX5 | |
| SCHEMBL9474500 | 0.87 | ALOX5 (0.77) | ALOX5PARP10 | |
| SCHEMBL9473784 | 0.87 | ALOX5 (0.77) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996032377-A1 | LIPOXYGENASE AND CYCLOOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-10-17 | — | — | WO | disclosed |
| US-5516789-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0292699-B1 | Urea based lipoxygenase inhibiting compounds | ABBOTT LAB (US) | 1994-03-23 | — | — | EP | disclosed |
| US-5185363-A | Administering for treatment of inflammatory diseases | ABBOTT LABORATORIES (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0292699-A2 | Urea based lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1988-11-30 | — | — | EP | disclosed |